Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03061734
Other study ID # ANODYNE-1
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date February 18, 2017
Est. completion date February 8, 2018

Study information

Verified date April 2021
Source Allodynic Therapeutics, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.


Recruitment information / eligibility

Status Completed
Enrollment 92
Est. completion date February 8, 2018
Est. primary completion date February 8, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female 18 years of age or older. 2. History of migraine with or without aura according to the International Classification of Headache Disorders (ICHD)-3rd edition (beta version) for at least one-year with first migraine prior to age 50. 3. Migraine-associated nausea with =half of migraine attacks. 4. 2 - 8 migraines per month in each of the previous 3 months. 5. The patient is able to complete study questionnaires, comply with the study requirements and restrictions, and willing to provide written informed consent and authorize HIPAA. 6. The female patient who is premenopausal or postmenopausal less than 1 year, or have not had surgical sterilization (i.e., tubal ligation, partial or complete hysterectomy) must have a negative urine pregnancy test, be non-lactating, and commit to using adequate and reliable contraception throughout the study (e.g., barrier with additional spermicidal, intra-uterine device, hormonal contraception). The male patient must be surgically sterile or commit to the use of 2 different methods of birth control during the study and for 28 days after taking the study drug. Exclusion Criteria: 1. The patient in the opinion of the investigator, may have medication-overuse headache pain (as defined by ICHD - 3 beta criteria for medication-overuse headache), (analgesic, opioid, ergotamine or triptan overuse) during the 3 months preceding screening. 2. The patient in the opinion of the investigator has chronic migraine (as defined by ICHD - 3 beta criteria for chronic migraine). 3. History of cluster headache or neurologically complicated migraine (hemiplegic, basilar, retinal, ophthalmoplegic migraine). 4. Initiation or change in medications with possible migraine prophylactic effects during 3 months before inclusion into the trial (E.g., calcium channel blockers, tricyclic antidepressants, beta-blockers, selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine re-uptake inhibitors (SNRIs), or Botox). 5. Any concurrent medical or psychiatric condition, this includes, but is not limited to chronic unstable debilitating diseases, significant renal or hepatic impairment. 6. A history within the previous 3 years of abuse of any drug, prescription, illicit, or alcohol. 7. The Female patient is pregnant or breast-feeding. The Male patient is not practicing 2 different methods of birth control with their partner during the study, and for 28 days after the investigational drug last dose or will not remain abstinent during the study, and for 28 days after the last dose. 8. Use of opiates or barbiturates more than 3 days per month. 9. Known-hypersensitivity reaction to any of the components of the investigational drug. 10. Consumption of analgesic medication for other conditions on a regular basis, (nonsteroidal anti-inflammatory drugs, or acetaminophen, or muscle relaxants). 11. Use of emergency care treatment more than 3 times in the previous 6 months. 12. Participation in another study with an investigational drug within 30 days prior to randomization and/or a plan to participate during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Naltrexone and Acetaminophen
Naltrexone plus acetaminophen
Naltrexone and Acetaminophen-High Dose
Naltrexon (high dose) plus acetaminophen
Naltrexone Alone (regular dose)
Naltrexone Alone plus Placebo
Acetaminophen Alone
Acetaminophen Alone plus Placebo
Matching Placebo
Two Placebo capsules

Locations

Country Name City State
United States Annette C. Toledano MD North Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
Allodynic Therapeutics, LLC

Country where clinical trial is conducted

United States, 

References & Publications (11)

Dewall CN, Macdonald G, Webster GD, Masten CL, Baumeister RF, Powell C, Combs D, Schurtz DR, Stillman TF, Tice DM, Eisenberger NI. Acetaminophen reduces social pain: behavioral and neural evidence. Psychol Sci. 2010 Jul;21(7):931-7. doi: 10.1177/095679761 — View Citation

Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, Patel SJ, Crysdale NY, Harrison JA, Maier SF, Rice KC, Watkins LR. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). E — View Citation

Kaki AM, El-Yaski AZ, Youseif E. Identifying neuropathic pain among patients with chronic low-back pain: use of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. Reg Anesth Pain Med. 2005 Sep-Oct;30(5):422-8. — View Citation

Kato J, Svensson CI. Role of extracellular damage-associated molecular pattern molecules (DAMPs) as mediators of persistent pain. Prog Mol Biol Transl Sci. 2015;131:251-79. doi: 10.1016/bs.pmbts.2014.11.014. Epub 2015 Jan 30. Review. — View Citation

Lewis SS, Loram LC, Hutchinson MR, Li CM, Zhang Y, Maier SF, Huang Y, Rice KC, Watkins LR. (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain. 2012 May;13(5):498- — View Citation

Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med. 2000 Dec 11-25;160(22):3486-92. — View Citation

Su M, Ran Y, He Z, Zhang M, Hu G, Tang W, Zhao D, Yu S. Inhibition of toll-like receptor 4 alleviates hyperalgesia induced by acute dural inflammation in experimental migraine. Mol Pain. 2018 Jan-Dec;14:1744806918754612. doi: 10.1177/1744806918754612. Epu — View Citation

Wang X, Zhang Y, Peng Y, Hutchinson MR, Rice KC, Yin H, Watkins LR. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Br J Pharmacol. 2016 Mar;173(5):856-69. doi: 10.111 — View Citation

Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun. 2007 Feb;21(2):131-46. — View Citation

Wieseler J, Ellis A, McFadden A, Stone K, Brown K, Cady S, Bastos LF, Sprunger D, Rezvani N, Johnson K, Rice KC, Maier SF, Watkins LR. Supradural inflammatory soup in awake and freely moving rats induces facial allodynia that is blocked by putative immune — View Citation

Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009 May-Jun;10(4):663-72. doi: 10.1111/j.1526-4637.2009.00613.x. Epub 2009 Apr 22. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other % of patients who experienced adverse events treatment related Adverse Events 48 hours
Primary % of patients reporting no headache pain. Self-reported headache pain on a four-point Likert scale. 2 hours post-dose
Primary % of patients having absence of most bothersome migraine-associated symptom (MBS). MBS was prospectively identified at baseline. Self-reported MBS as present or absent. 2 hours post-dose
Primary % of patients who have "sustained pain freedom" Defined as having no headache pain at 2 hours after dose, with no use of rescue medication and no relapse of headache pain within 24 hours after administration of the investigational drug. 24-hour post-dose.
Secondary % of patients having absence of nausea, photophobia, phonophobia, and neck/shoulder pain Self-reported the current status of their associated symptom as present or absent. 24-hour post-dose.
Secondary % of patients who used rescue medications 2-24 hours
Secondary % of patients who had headache pain relapse. Defined as the return of headache of any severity within 48 hours after administration of the investigational drug, when the patient was pain-free at 2 hours after the administration of the investigational drug. 2-48 hours
See also
  Status Clinical Trial Phase
Completed NCT00792636 - A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period Phase 4
Completed NCT00383162 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Phase 3
Completed NCT01986088 - Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study Phase 3
Completed NCT02605174 - Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine Phase 3
Completed NCT01978496 - Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine Phase 3
Completed NCT01989936 - Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan Phase 3
Completed NCT06245902 - An Acute Migraine Factorial Study Phase 2
Completed NCT00382993 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Phase 3
Completed NCT01986270 - Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo Phase 3
Completed NCT03194555 - The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination Phase 2